GPR-related gene signatures and TME are closely related to BLCA prognosis and immunotherapy, and GPR-related gene signature can be a useful tool to assess BLCA prognosis and immunotherapy response. Here, ALDH18A1 is linked to bladder transitional cell carcinoma.